Onesource Specialty Pharma Limited Q4 FY25 earnings call summary

Earnings call of 6 May 2025, summarised by AI from the filing.

OneSource reported Q4 FY25 revenue of ₹4,260 million, up 22%, and reaffirmed FY28 guidance of $400 million revenue with 38-40% EBITDA margin.

Key takeaways

1. FY28 guidance $400 million revenue and 38-40% EBITDA margin, organically.
2. Debt reduction Net debt reduced to ₹4,707 million; aim to be net debt free in 2-3 years.
3. Capacity expansion Expanding from 40 million to over 90 million capacity by December.
4. Approval risk Commercial supplies depend on partners receiving regulatory approvals and freedom to operate.

Original filing on BSE

Onesource Specialty Pharma Limited Q1 FY27 results

As filed: Revenue ₹449 cr (+37% year on year), EBITDA ₹123 cr (+39% year on year), PAT ₹25.0 cr, EBITDA margin 27.5% (+25 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹428 cr (+1% year on year), EBITDA ₹91.9 cr (−49% year on year), PAT ₹4.6 cr (−100% year on year), EBITDA margin 21.5% (−1,000 bps). Score 9 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −9.9% in 30 days (Nifty 500: +1.0%).
• Q3 FY26: Revenue ₹290 cr (−26% year on year), EBITDA ₹17.3 cr (−88% year on year), PAT −₹88.7 cr, EBITDA margin 6.0% (−1,000 bps). Score 0 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 23% from last quarter. Share price after the results: −25.0% in 30 days (Nifty 500: +0.7%).
• Q2 FY26: Revenue ₹376 cr (+300% year on year), EBITDA ₹107 cr, PAT ₹10.0 cr, EBITDA margin 28.5% (+1,000 bps). Score 88 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Other income 50% of PBT. Tax rate -83%. Not enough history for a trend yet: scored on growth alone. Share price after the results: −5.6% in 30 days (Nifty 500: −0.6%).
• Q1 FY26: Revenue ₹321 cr, EBITDA ₹80.0 cr, PAT ₹25.0 cr, EBITDA margin 24.9%. Not scored. No result for the same quarter last year. Share price after the results: −4.1% in 29 days (Nifty 500: −2.5%).
• Q4 FY25: Revenue ₹477 cr, EBITDA ₹237 cr, PAT ₹174 cr, EBITDA margin 49.7%. Not scored. No result for the same quarter last year. Share price after the results: +17.5% in 30 days (Nifty 500: +2.8%).
• Q3 FY25: Revenue ₹337 cr, EBITDA ₹101 cr, PAT −₹73.0 cr, EBITDA margin 30.0%. Not scored. No result for the same quarter last year.
• Q2 FY25: Revenue ₹68.0 cr, EBITDA ₹0.0 cr, PAT −₹40.0 cr, EBITDA margin 0.0%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Onesource Specialty Pharma Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (25 Jul 2026), Results press release (24 Jul 2026)
• Q4 FY26: Earnings call (13 May 2026), Results deck (13 May 2026), Results press release (13 May 2026)
• Q3 FY26: Earnings call (24 Jan 2026)
• Q2 FY26: Earnings call (12 Nov 2025), Results deck (12 Nov 2025), Results press release (11 Nov 2025)
• Q1 FY26: Earnings call (5 Aug 2025)
• Q4 FY25: Earnings call (6 May 2025)
• Other events: Investor presentation (3 Sep 2026), Strategy deck (26 Sep 2025)